发布求助
文献互助 智能选刊 最新文献

Trends in Endocrinology & Metabolism最新文献

筛选
英文 中文
NAD augmentation as a disease-modifying strategy for neurodegeneration. NAD增强作为神经退行性疾病的一种改善策略。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-25 DOI: 10.1016/j.tem.2025.03.013
Christian Dölle,Charalampos Tzoulis
{"title":"NAD augmentation as a disease-modifying strategy for neurodegeneration.","authors":"Christian Dölle,Charalampos Tzoulis","doi":"10.1016/j.tem.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.013","url":null,"abstract":"Neurodegenerative diseases (NDDs) pose a significant and rapidly growing global health challenge, but there are no effective therapies to delay or halt progression. In recent years augmentation of nicotinamide adenine dinucleotide (NAD) has emerged as a promising disease-modifying strategy that targets multiple key disease pathways across multiple NDDs, such as mitochondrial dysfunction, energy deficits, proteostasis, and neuroinflammation. Several early clinical trials of NAD augmentation have been completed, and many more are currently underway, reflecting the growing optimism and urgency within the field. We discuss the rationale and evolving therapeutic landscape of NAD augmentation. We argue that, to fully realize its therapeutic potential, it is essential to determine the specific contexts in which NAD supplementation is most effective and to address crucial knowledge gaps.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The interplay between endometriosis and obesity. 子宫内膜异位症和肥胖之间的相互作用。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-24 DOI: 10.1016/j.tem.2025.03.011
Md Saidur Rahman,Yunjeong Park,Hossein Hosseinirad,Jung-Ho Shin,Jae-Wook Jeong
{"title":"The interplay between endometriosis and obesity.","authors":"Md Saidur Rahman,Yunjeong Park,Hossein Hosseinirad,Jung-Ho Shin,Jae-Wook Jeong","doi":"10.1016/j.tem.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.011","url":null,"abstract":"Endometriosis, characterized by uterine-like tissue growth outside the uterus, is a complex disorder with significant clinical implications. This review explores how body composition - both low body mass index (BMI) and obesity - modulates endometriosis progression through metabolic, hormonal, and immune-inflammatory pathways. Obesity-driven leptin signaling emerges as a pivotal link, promoting systemic inflammation, angiogenesis, and lesion persistence via Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Shared molecular mechanisms between endometriosis and obesity highlight opportunities for precision medicine and targeted therapies. By addressing leptin-driven pathways and metabolic dysfunction, we introduce innovative strategies, offering novel insights into the improved management of this multifaceted condition.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics and epigenetics in gestational diabetes contributing to type 2 diabetes. 妊娠期糖尿病与2型糖尿病的遗传学和表观遗传学关系。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-24 DOI: 10.1016/j.tem.2025.03.014
Dewei Kong,Oliwia Kowalik,Emma Garratt,Keith M Godfrey,Shiao-Yng Chan,Adrian Kee Keong Teo
{"title":"Genetics and epigenetics in gestational diabetes contributing to type 2 diabetes.","authors":"Dewei Kong,Oliwia Kowalik,Emma Garratt,Keith M Godfrey,Shiao-Yng Chan,Adrian Kee Keong Teo","doi":"10.1016/j.tem.2025.03.014","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.014","url":null,"abstract":"Gestational diabetes mellitus (GDM) is a common pregnancy complication and a risk factor for the subsequent development of type 2 diabetes (T2D) in mothers and of several metabolic diseases in offspring. However, the molecular underpinnings of these risks are not well understood. Genome-wide association studies (GWAS) and epigenetic studies may provide complementary insights into the causal relationships between GDM exposure and maternal/offspring metabolic outcomes. In this review we discuss the potential pathophysiological roles of specific genetic variants and commonly reported differentially methylated loci in GDM development, and their link to the progression to T2D in both the mother and the offspring in later life, pointing to the potential for tailored interventional strategies based on these genetic and epigenetic mechanisms.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising results but caution needed in GLP-1RA large scale epidemiology. 有希望的结果，但需要谨慎的GLP-1RA大规模流行病学。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-24 DOI: 10.1016/j.tem.2025.03.015
Salil V Deo,Naveed A Sattar
{"title":"Promising results but caution needed in GLP-1RA large scale epidemiology.","authors":"Salil V Deo,Naveed A Sattar","doi":"10.1016/j.tem.2025.03.015","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.015","url":null,"abstract":"Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis. However, many apparent novel findings need testing or validation in randomized trials.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
(Poly)phenols as bioactive constituents linked to dietary fibre metabolic fate. （聚）酚作为与膳食纤维代谢命运相关的生物活性成分。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-16 DOI: 10.1016/j.tem.2025.03.012
Jara Pérez-Jiménez,Yolanda Sanz,Rosa M Lamuela-Raventós
{"title":"(Poly)phenols as bioactive constituents linked to dietary fibre metabolic fate.","authors":"Jara Pérez-Jiménez,Yolanda Sanz,Rosa M Lamuela-Raventós","doi":"10.1016/j.tem.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.012","url":null,"abstract":"","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fumarate integrates metabolism and immunity in diseases. 富马酸在疾病中整合代谢和免疫。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-16 DOI: 10.1016/j.tem.2025.03.008
Jie Cheng,Yifeng Xiao,Peng Jiang
{"title":"Fumarate integrates metabolism and immunity in diseases.","authors":"Jie Cheng,Yifeng Xiao,Peng Jiang","doi":"10.1016/j.tem.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.008","url":null,"abstract":"Fumarate is a key metabolite produced primarily by the tricarboxylic acid (TCA) and urea cycles. In addition to having a metabolic role, its electrophilicity enables it to covalently modify cysteines; moreover, because of its α-ketoglutarate (α-KG)-like structure, it can also act as a competitive inhibitor of α-KG-dependent dioxygenases for epigenetic remodeling. Recent advances have broadened the role of fumarate as a bridge between metabolism and both innate and adaptive immunity, suggesting potentially important functions in anticancer immunity and autoimmune diseases. Here we review the connections between fumarate metabolism and immunity; we describe the mechanisms of fumarate regulation in cancer, autoimmunity, and other diseases; and we explore the clinical implications of fumarate and its esters for immunotherapy.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adipose tissue-targeting nanomedicines for obesity pharmacotherapy. 脂肪组织靶向纳米药物用于肥胖药物治疗。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-14 DOI: 10.1016/j.tem.2025.03.010
Lingling Wang,Qingyi Jia,Jinhan He,Yanping Li
{"title":"Adipose tissue-targeting nanomedicines for obesity pharmacotherapy.","authors":"Lingling Wang,Qingyi Jia,Jinhan He,Yanping Li","doi":"10.1016/j.tem.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.010","url":null,"abstract":"The increasing global prevalence of obesity presents a substantial challenge to public health. Current nutrient-stimulated hormone (NuSH)-based therapeutics are hindered by receptor desensitization, muscle loss, and weight regain. The adipose tissue, the primary organ responsible for energy storage and metabolic management, is a promising target for obesity treatment. Nanomedicine holds promise to precisely deliver medication to the adipose tissue to maximize therapeutic efficacy and minimize off-target effects; indeed, various adipose tissue-targeting nanomedicines have shown impressive anti-obesity effects by optimizing drug pharmacokinetic profiles and reducing nonspecific distribution in preclinical studies. Here we examine the current state of the art of adipose tissue-targeting nanomedicines, offering insights into recent advances, future possibilities, and the remaining challenges associated with their application in obesity treatment.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting PKLR in liver diseases 靶向PKLR治疗肝脏疾病
Trends in Endocrinology & Metabolism Pub Date : 2025-04-11 DOI: 10.1016/j.tem.2025.03.009
Meng Yuan, Mengnan Shi, Hong Yang, Sajda Ashraf, Shazia Iqbal, Hasan Turkez, Jan Boren, Cheng Zhang, Mathias Uhlén, Ozlem Altay, Adil Mardinoglu
{"title":"Targeting PKLR in liver diseases","authors":"Meng Yuan, Mengnan Shi, Hong Yang, Sajda Ashraf, Shazia Iqbal, Hasan Turkez, Jan Boren, Cheng Zhang, Mathias Uhlén, Ozlem Altay, Adil Mardinoglu","doi":"10.1016/j.tem.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.009","url":null,"abstract":"Pyruvate kinase is a key regulator in hepatic glucose metabolism, encoded by the gene pyruvate kinase liver/red blood cells (<ce:italic>PKLR</ce:italic>). Systems biology-based approaches, including metabolic and gene co-expression networks analyses, as well as genome-wide association studies (GWAS), have led to the identification of <ce:italic>PKLR</ce:italic> as a pivotal gene influencing liver metabolism in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). Here, we review the critical role of <ce:italic>PKLR</ce:italic> in MASLD and HCC progression and examine the effects of <ce:italic>PKLR</ce:italic> modulation both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>. We also discuss the development of therapeutic strategies for patients with MASLD and HCC by modulating <ce:italic>PKLR</ce:italic>, highlighting its promising future in a broader range of liver diseases.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease. 推进代谢功能障碍相关脂肪变性肝病的精准医学研究。
Trends in Endocrinology & Metabolism Pub Date : 2025-04-10 DOI: 10.1016/j.tem.2025.03.006
Bryan A Priego-Parra,Rocío Gallego-Durán,Berenice M Román-Calleja,José Antonio Velarde-Ruiz Velasco,Manuel Romero-Gómez,Jordi Gracia-Sancho
{"title":"Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease.","authors":"Bryan A Priego-Parra,Rocío Gallego-Durán,Berenice M Román-Calleja,José Antonio Velarde-Ruiz Velasco,Manuel Romero-Gómez,Jordi Gracia-Sancho","doi":"10.1016/j.tem.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.tem.2025.03.006","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively.","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subscription and Copyright Information 订阅及版权资料
Trends in Endocrinology & Metabolism Pub Date : 2025-03-03 DOI: 10.1016/s1043-2760(25)00031-1
{"title":"Subscription and Copyright Information","authors":"","doi":"10.1016/s1043-2760(25)00031-1","DOIUrl":"https://doi.org/10.1016/s1043-2760(25)00031-1","url":null,"abstract":"","PeriodicalId":23301,"journal":{"name":"Trends in Endocrinology & Metabolism","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信